Thursday, 30 July 2015
Pascal Soriot, Chief Executive Officer, commenting on the results, said:
“We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of1 top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas.
I’m particularly pleased by the pace of progress in Oncology, with new approvals for both Iressa and Faslodex accompanied by regulatory submissions for AZD9291 and cediranib. The strong performance of the growth platforms and the subsequent upgrade to top-line guidance, together with increased R&D productivity reaffirm the confidence we have in our ability to navigate the final impacts from the loss of exclusivity and meet our revenue targets.”
H1 2015 RESULTS
Announced on Thursday 30 July 2015